ADIPOQ and metabolic syndrome: Frühbeck et al. set a value that accurately accounted for cardiometabolic risk; patients with obesity, type II diabetes mellitus, and metabolic syndrome all had leptin-adiponectin relationships that met the criteria for increased risk [219].